C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 116 filers reported holding C4 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,334 | -8.9% | 45,341 | +34.7% | 0.00% | – |
| Q2 2023 | $92,589 | -42.7% | 33,669 | -34.6% | 0.00% | – |
| Q1 2023 | $161,672 | -86.0% | 51,488 | -73.6% | 0.00% | – |
| Q4 2022 | $1,151,420 | -5.7% | 195,156 | +40.2% | 0.00% | – |
| Q3 2022 | $1,221,000 | +163.1% | 139,187 | +126.3% | 0.00% | – |
| Q2 2022 | $464,000 | -81.6% | 61,511 | -40.7% | 0.00% | – |
| Q1 2022 | $2,517,000 | -23.1% | 103,778 | +2.1% | 0.00% | – |
| Q4 2021 | $3,274,000 | +240.0% | 101,673 | +371.8% | 0.00% | – |
| Q3 2021 | $963,000 | -25.8% | 21,551 | -37.2% | 0.00% | – |
| Q2 2021 | $1,298,000 | -28.0% | 34,305 | -29.7% | 0.00% | – |
| Q1 2021 | $1,804,000 | +788.7% | 48,774 | +695.7% | 0.00% | – |
| Q4 2020 | $203,000 | – | 6,130 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |